{
    "name": "testosterone intranasal",
    "comment": "Rx",
    "other_names": [
        "Natesto"
    ],
    "classes": [
        "Androgens"
    ],
    "source": "https://reference.medscape.com/drug/natesto-testosterone-intranasal-999929",
    "pregnancy": {
        "common": [
            "Pregnancy Category: X",
            "Lactation: Contraindicated; unknown if excreted into human breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Contraindicated; unknown if excreted into human breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Men with carcinoma of the breast",
                "Men with known or suspected prostate cancer",
                "Pregnant or breast-feeding women; testosterone may cause fetal harm"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids; anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions",
                "Nasal adverse reactions reported, including nasopharyngitis, rhinorrhea, epistaxis, nasal discomfort, and nasal scabbing",
                "Monitor for nasal signs and symptoms; not recommended for patients with chronic nasal conditions or alterations in nasal anatomy (eg, nasal or sinus surgery, nasal fracture within previous 6 months, deviated anterior nasal septum, mucosal inflammatory disorders [Sjogren syndrome], sinus disease)",
                "Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms",
                "Increased hematocrit (polycythemia), reflective of increased red blood cell mass, may require discontinuation; increases risk for thromboemolism",
                "Venous thromboembolism, including DVT and PE reported in patients using testosterone products; these observations have included patients with and without polycythemia; evaluate signs or symptoms consistent with DVT or PE; if venous thromboembolic event suspected, discontinue treatment with testosterone and initiate appropriate workup and management",
                "Women and children should not use testosterone intranasal",
                "Prolonged use of high doses of orally active 17-alpha-alkyl metabolic-endocrine#androgens (methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatitis, hepatic neoplasms, cholestatic hepatitis, and jaundice)",
                "Edema with or without CHF may be a complication in patients with preexisting cardiac, renal, or hepatic disease",
                "Exogenous administration of metabolic-endocrine#androgens may lead to azoospermia",
                "Gynecomastia may develop and may persist in patients being treated with metabolic-endocrine#androgens",
                "Sleep apnea may occur in those with risk factors",
                "Androgens should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria)",
                "Androgens may decrease concentrations of thyroxine-binding globulins, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4",
                "Monitor serum testosterone, prostate-specific antigen (PSA), hemoglobin, hematocrit, liver function tests, and lipid concentrations periodically",
                "Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with the use of testosterone replacement therapy"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "betamethasone",
            "description": {
                "common": "testosterone intranasal, betamethasone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "corticotropin",
            "description": {
                "common": "testosterone intranasal, corticotropin.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "testosterone intranasal, cortisone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "testosterone intranasal, dexamethasone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "testosterone intranasal, fludrocortisone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "testosterone intranasal, hydrocortisone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "testosterone intranasal, methylprednisolone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "testosterone intranasal and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisolone",
            "description": {
                "common": "testosterone intranasal, prednisolone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "testosterone intranasal, prednisone.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "testosterone intranasal, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of testosterone intranasal by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "testosterone intranasal, triamcinolone acetonide injectable suspension.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration increases risk for edema, particularly in patients with cardiac, renal, or hepatic disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "testosterone intranasal will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "testosterone intranasal increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "testosterone intranasal increases effects of insulin aspart protamine/insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "testosterone intranasal increases effects of insulin degludec by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "testosterone intranasal increases effects of insulin degludec/insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "testosterone intranasal increases effects of insulin detemir by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "testosterone intranasal increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "testosterone intranasal increases effects of insulin glulisine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "testosterone intranasal increases effects of insulin inhaled by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "testosterone intranasal increases effects of insulin isophane human/insulin regular human by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "testosterone intranasal increases effects of insulin lispro by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "testosterone intranasal increases effects of insulin lispro protamine/insulin lispro by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "testosterone intranasal increases effects of insulin NPH by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "testosterone intranasal increases effects of insulin regular human by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nasopharyngitis",
            "percent": "8.2"
        },
        {
            "name": "Rhinorrhea",
            "percent": "7.8"
        },
        {
            "name": "Epistaxis",
            "percent": "6.5"
        },
        {
            "name": "Nasal discomfort",
            "percent": "5.9"
        },
        {
            "name": "Increased PSA",
            "percent": "5.1-5.8"
        },
        {
            "name": "Nasal scab",
            "percent": "5.2"
        },
        {
            "name": "Parosmia",
            "percent": "5.2"
        },
        {
            "name": "Headache",
            "percent": "3.8-4.3"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "4.2"
        },
        {
            "name": "Nasal dryness",
            "percent": "4.2"
        },
        {
            "name": "Nasal congestion",
            "percent": "3.9"
        },
        {
            "name": "Bronchitis",
            "percent": "3.8"
        },
        {
            "name": "Sinusitis",
            "percent": "3.8"
        },
        {
            "name": "ncreased blood pressure",
            "percent": "2-3"
        },
        {
            "name": "Dysgeusia",
            "percent": "2-3"
        },
        {
            "name": "Cough",
            "percent": "2-3"
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Venous thromboembolism",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "stroke",
            "percent": null
        }
    ]
}